Fatty liver largely explains associations of subclinical hypothyroidism with insulin resistance, metabolic syndrome, and subclinical coronary atherosclerosis


Endocrinology Department, 1Interventional Cardiology Department and 2Computed Tomography Department, Instituto Nacional de Cardiología ‘Ignacio Chávez’, Juan Badiano 1, Col. Sección XVI, C.P. 14080 Tlalpan, México D.F., Mexico

Abstract

Background: The association of subclinical hypothyroidism (SCH) with insulin resistance, metabolic syndrome (MS), and coronary atherosclerosis is uncertain.

Objective: To investigate the role of increased intrahepatic fat in the association of SCH with insulin resistance, MS, and coronary atherosclerosis.

Design, patients, and methods: We conducted a cross-sectional study in a sample of 753 subjects (46% males) aged 35–70 years with no history of diabetes, renal, hepatic, thyroid, or coronary heart disease, and were participants of the Genetics of Atherosclerotic Disease study. SCH was defined as a high serum TSH level with normal free thyroxine concentration. Fatty liver (FL), coronary artery calcification (CAC), and abdominal visceral adipose tissue were assessed by computed tomography. Cross-sectional associations of SCH with and without FL, with MS, insulin resistance, and subclinical atherosclerosis defined as a CAC score ≥ 0, were examined in logistic regression models.

Results: SCH was observed in 17.7% of the population studied. The prevalence of FL was similar in both euthyroid and SCH subjects (31.8 vs 27.8%, \( P = 0.371 \)). SCH plus FL subjects were heavier and had more metabolic abnormalities compared with SCH plus normal liver subjects. In multivariate-adjusted logistic regression analyses, SCH plus FL was associated with MS (odds ratio (OR): 2.73, 95% CI: 1.26–5.92), insulin resistance (OR: 4.91, 95% CI: 1.63–14.75), and CAC score ≥ 0 (OR: 3.05, 95% CI: 1.20–7.76). SCH without FL showed no associations.

Conclusion: SCH with FL is associated with increased odds of MS, insulin resistance, and CAC, independent of potential confounders.

Introduction

Subclinical hypothyroidism (SCH), defined as an elevated serum thyroid-stimulating hormone (TSH) concentration and normal free thyroxine (FT4) level, is a common condition with a reported prevalence between 4 and 20% (1). Increased hepatic fat content, in the absence of excessive alcohol consumption or other specific causes of steatosis, has been called non-alcoholic fatty liver disease (NAFLD) (2). At present, this condition is recognized as the most common liver disease, affecting 20–30% of the adult population (3). NAFLD is associated with a wide range of metabolic abnormalities, including glucose intolerance, dyslipidemia, and insulin resistance (4, 5), and also with atherosclerosis in coronary arteries (6).
Whether or not SCH is related to cardiovascular risk factors and coronary heart disease (CHD) is controversial. Although some studies have reported associations of SCH with insulin resistance (7, 8), metabolic syndrome (MS) (7, 9), and CHD (10, 11), not all previous findings have been consistent (12, 13, 14). Recent studies in adults (9, 15, 16) and children (7) have shown that SCH is closely associated with NAFLD independent of potential confounders. Based on these findings and considering that insulin resistance is a key feature of NAFLD, we hypothesized that the relationship of SCH with cardiometabolic risk factors and CHD may be influenced by the presence of increased intrahepatic fat. To test this hypothesis, in this investigation, we analyzed the associations of SCH with and without fatty liver (FL) with insulin resistance, MS, and coronary artery calcification (CAC) score > 0 as a surrogate marker for coronary atherosclerosis.

Subjects and methods
The study population included participants of the Genetics of Atherosclerotic Disease (GEA) study. The GEA study was designed to examine the genomic bases of CHD and assess relationships between traditional and emerging risk factors with clinical and subclinical atherosclerotic vascular diseases in an adult Mexican population (17). Briefly, a convenience sample of 1000 CHD patients and 1500 control subjects aged 35–70 years is being recruited from residents in Mexico City. Patients with established premature CHD were selected from the outpatient clinic of the National Institute of Cardiology. Volunteer control participants with a negative family history of premature CHD and no personal history of cardiovascular disease were recruited from blood bank donors, and through brochures posted in social service centers. Coronary patients and control subjects with a history of renal, liver, thyroid, or malignant disease, as well as those on treatment with corticosteroids, were excluded. The GEA study was approved by the Institutional Review Board of the National Institute of Cardiology and conducted according to the Declaration of Helsinki. Written informed consent was obtained from participants.

This study is a cross-sectional analysis of the baseline measurements of 1252 control subjects included in the GEA study from June 2008 to February 2013. None of the subjects were on medication therapy that could affect thyroid status. As diabetes is associated with higher incidence rates of FL and CAC (18), we excluded all subjects with type 2 diabetes (n = 155). Participants with alcohol consumption ≥ 20 g/day (n = 23), and those using statins (n = 89) or β-blockers (n = 48) were also excluded. We also excluded 184 subjects with unavailable insulin measurements. The final study population for this analysis comprised 753 subjects. When compared with the included participants, excluded participants with no insulin values were younger (53 ± 9 vs 50 ± 9 years old; P < 0.01) and had lower systolic blood pressure levels (116 ± 17 vs 113 ± 15 mmHg; P = 0.042). No other differences were observed.

All participants in this study answered structured questionnaires that provide detailed information regarding family history, demographics, diet, physical activity, medications, smoking, and alcohol intake. Insulin and diastolic blood pressures were measured after subjects rested for at least 10 min, and the average of the second and third measurements was used as the blood pressure of the subject. Height, weight, and waist circumference were measured and BMI was calculated as weight in kilograms divided by height in meters squared. The MS was defined using the criteria from the American Heart Association/National Heart, Lung, and Blood Institute scientific statement on the MS (19), except for central obesity that was considered when waist circumference was > 90 cm in men and > 80 cm in women (20). Diabetes was defined by the American Diabetes Association criteria (21) and was also considered when participants reported glucose-lowering treatment or a physician diagnosis of diabetes. Insulin resistance was estimated using the homeostasis model assessment (HOMA-IR). The presence of insulin resistance was considered when the HOMA-IR values were ≥ 75th percentile (3.58 in women and 3.12 in men). These cutoff points were obtained from a GEA study sample of 101 men and 180 women without obesity and with normal values of blood pressure and fasting glucose and lipids.

Biochemical analyses
Venous blood samples were collected from subjects after a 12-h fast. Plasma glucose, total cholesterol, triglycerides, HDL-C, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were measured in fresh samples, using standardized enzymatic procedures in a Hitachi 902 analyzer (Hitachi Ltd). Accuracy and precision of lipid measurements in our laboratory are under periodic surveillance by the Centers for Disease Control and Prevention service (Atlanta, GA, USA). LDL-C was estimated using the DeLong et al. formula (22). Total high-sensitivity C-reactive protein (hs-CRP) levels were
determined by immunonephelometry on a BN Pro Spec nephelometer (Dade Behring GmbH, Marburg, Germany). Interassay coefficient of variation (CV) values were <6% for all of these assays. Plasma insulin concentrations were determined by a RIA (Millipore; RIA Kit, Cat. No. HI-14K, St Charles, MO, USA) the intra- and interassay CV values were 2.1 and 6.8% respectively.

Serum TSH and FT4 concentrations were measured by an electrochemiluminescent immunometric assay (Roche Diagnostics). TSH was considered normal if its value was between 0.3 and 4.5 mU/L, on the basis of previous studies that demonstrated an increased clinical risk above this cutoff point (23, 24). SCH was considered if the TSH level was elevated and FT4 level was within the normal range (11.97–18.02 pmol/l) (25).

Computed tomography study

Visceral adipose tissue (VAT), subcutaneous fat, liver and spleen attenuation, and coronary artery calcium were quantified by computed tomography in each participant. Computed tomography of the chest and abdomen were performed using a 64-channel multidetector helical computed tomography system (Somatom Sensation, Siemens, Malvern, PA, USA) and interpreted by experienced radiologists. Scans were read to assess and quantify the following: i) total abdominal, subcutaneous, and VAT areas as described by Kvist et al. (26); ii) liver to spleen attenuation ratio (L:SAR) as described by Longo et al. (27); and iii) CAC score using the Agatston method (28).

Subclinical atherosclerosis was defined as the presence of a CAC score >0 and hepatic steatosis as L:SAR ≤1.0 (18).

Statistical analysis

Data are expressed as mean ± S.D., median (interquartile range), or as frequencies for categorical variables. Comparisons were made using the t-test or the Mann–Whitney U test, as appropriate, for continuous variables, and by χ2 analysis for categorical variables. The association of SCH with MS, insulin resistance, and CAC score >0 according to the presence of FL was assessed by multivariate logistic regression adjusted for age, gender, BMI, VAT, hs-CRP, FT4 and LDL-C. When the CAC score >0 was assessed as the dependent variable, we additionally adjusted for MS components: triglycerides, HDL-C, hypertension, and fasting glucose. In all models, euthyroid subjects without FL were used as a referent group. The MS was used instead of each MS component to avoid overadjustment. The values of P<0.05 were considered statistically significant. All statistical procedures were performed using the SPSS software (SPSS version 15.0, Inc.).

Results

A sample of 620 euthyroid subjects (31.8% with FL) and 133 with SCH (27.8% with FL) was analyzed. Except for age, number of females, and HDL-C concentrations, which were higher in SCH subjects, no other differences were observed in the comparison between euthyroid and SCH groups as a whole. Furthermore, the prevalence of FL across quartiles of TSH was not significantly different (Q1, 31.4%; Q2, 33.3%; Q3, 29.10%; and Q4, 30.11%, X2: 0.83). To determine the influence of FL on the association of SCH with MS, insulin resistance, and CAC score >0, euthyroid and SCH groups were stratified according to the presence of FL (with (+) and without (−)). The anthropometric, clinical, and laboratory characteristics of the four groups are given in Table 1. Compared with euthyroid FL(−) subjects, those with FL(+), with or without SCH, were significantly associated with a higher BMI, waist circumference, VAT, and higher values of triglycerides, total cholesterol/HDL-C, glucose, insulin, HOMA-IR, hs-CRP, ALT, AST, and lower concentrations of HDL-C. Moreover, except for non-HDL-C and hs-CRP values, no differences were found between euthyroid FL(+) and SCH FL(+) subjects. In addition, as shown in Fig. 1, the prevalence of MS and elevated HOMA-IR was higher in FL(+) groups, whereas the CAC score >0 was higher only among subjects with SCH FL(+). Notably, despite their higher age, SCH FL(−) subjects had a metabolic pattern (Table 1) and prevalences of MS, insulin resistance, and CAC score >0 similar to euthyroid FL(−) subjects (Fig. 1).

Logistic regression models were used to assess whether SCH, with or without FL, was associated with MS, insulin resistance, and CAC score >0 (Table 2). Compared with the euthyroid FL(−) group, euthyroid FL(+) subjects were more likely to have MS and insulin resistance, independent of confounding factors, including their higher prevalence of visceral abdominal obesity (45 vs 79% respectively). However, subjects with the combination of SCH and FL(+) showed stronger associations with MS and insulin resistance. Additionally, only the latter subgroup showed a significant association with the presence of a CAC score >0, even after adjustment for multiple cardiovascular risk factors. On the other hand, the SCH FL(−) group did not show any association with cardio-metabolic abnormalities or CAC score >0. Owing to the relatively small number of subjects, analyses by gender were not performed.
Table 1  Clinical and biochemical characteristics of study subjects by thyroid function and FL. Values are expressed as mean ±S.D., median (interquartile range), or n (%); P values were obtained by the t-test, the Mann–Whitney U test, or the χ²-test respectively.

<table>
<thead>
<tr>
<th></th>
<th>Euthyroidism</th>
<th></th>
<th>P</th>
<th>Subclinical hypothyroidism</th>
<th></th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FL(−) (n = 423)</td>
<td>FL(+) (n = 197)</td>
<td>P</td>
<td>FL(−) (n = 96)</td>
<td>FL(+) (n = 37)</td>
<td>P</td>
</tr>
<tr>
<td>Age (years)</td>
<td>52 ± 9.6</td>
<td>51.80 ± 8.15</td>
<td>NS</td>
<td>56.1 ± 8.4†</td>
<td>53.24 ± 8.25</td>
<td>NS</td>
</tr>
<tr>
<td>Gender (female)</td>
<td>234 (55.3)</td>
<td>88 (44.7)</td>
<td>0.013</td>
<td>63 (65.6)</td>
<td>22 (59.5)</td>
<td>NS</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>27.3 ±4.3</td>
<td>30.0 ±4.16</td>
<td>&lt; 0.01</td>
<td>27.6 ± 3.9</td>
<td>30.5 ± 3.9†</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>91.5 ± 12</td>
<td>99.4 ± 12</td>
<td>&lt; 0.01</td>
<td>91.5 ± 10</td>
<td>99.5 ± 10†</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Visceral adipose tissue (cm²)</td>
<td>126 (89–170)</td>
<td>173 (145–220)</td>
<td>&lt; 0.01</td>
<td>133 (101–174)</td>
<td>178 (130–233)†</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>115 ± 18</td>
<td>118 ± 15</td>
<td>0.025</td>
<td>116 ± 19</td>
<td>120 ± 17</td>
<td>NS</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>71 ± 9.4</td>
<td>73.8 ± 10</td>
<td>&lt; 0.01</td>
<td>71.0 ± 10</td>
<td>73.13 ± 9.7</td>
<td>NS</td>
</tr>
<tr>
<td>TC (mmol/l)</td>
<td>4.97 ± 0.96</td>
<td>4.97 ± 1.01</td>
<td>NS</td>
<td>5.05 ± 0.88</td>
<td>5.28 ± 1.04</td>
<td>NS</td>
</tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>1.44 (1.10–1.99)</td>
<td>1.79 (1.36–2.46)</td>
<td>&lt; 0.01</td>
<td>1.44 (1.13–1.97)</td>
<td>1.84 (1.58–2.91)†</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>HDL-C (mmol/dl)</td>
<td>1.0 (0.98–1.48)</td>
<td>1.03 (0.88–1.27)</td>
<td>&lt; 0.01</td>
<td>1.30 (1.09–1.50)</td>
<td>1.07 (0.91–1.27)*</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Non-HDL-C (mmol/l)</td>
<td>3.63 (3.11–4.22)</td>
<td>3.83 (3.24–4.35)</td>
<td>NS</td>
<td>3.60 (3.19–4.20)</td>
<td>4.27 (3.29–4.84)†</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>TC/HDL-C</td>
<td>4.0 (3.3–4.9)</td>
<td>4.7 (3.9–5.6)</td>
<td>&lt; 0.01</td>
<td>3.8 (3.2–4.9)</td>
<td>4.6 (4.0–6.0)†</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Fasting glucose (mmol/l)</td>
<td>4.94 ± 0.50</td>
<td>5.22 ± 0.56</td>
<td>&lt; 0.01</td>
<td>4.89 ± 0.50</td>
<td>5.33 ± 0.61†</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Insulin (µU/ml)</td>
<td>14.7 (11–20)</td>
<td>22.6 (18–29)</td>
<td>&lt; 0.01</td>
<td>14.9 (11–19)</td>
<td>25.7 (17–28)†</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>3.1 (2.2–4.5)</td>
<td>5.2 (3.8–7.0)</td>
<td>&lt; 0.01</td>
<td>3.0 (2.4–4.2)</td>
<td>5.6 (4.4–6.9)†</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>hs-CRP (nmol/l)</td>
<td>12.9 (6.7–25.7)</td>
<td>19.2 (10.5–38.1)</td>
<td>&lt; 0.01</td>
<td>11.8 (6.7–22.9)</td>
<td>33.7 (14.3–52.4)†</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Alanine aminotransferase (U/l)</td>
<td>21 (16–27)</td>
<td>34 (24–51)</td>
<td>&lt; 0.01</td>
<td>20 (15–27)</td>
<td>29.5 (25.5–42)†</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Aspartate aminotransferase (U/l)</td>
<td>23 (19–28)</td>
<td>29 (24–38)</td>
<td>&lt; 0.01</td>
<td>25 (20–29)</td>
<td>28.5 (24.5–36)†</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Thyroid-stimulating hormone (mU/l)</td>
<td>2.3 (1.7–3.0)</td>
<td>2.2 (1.7–2.9)</td>
<td>NS</td>
<td>6.18 (5.1–8.3)†</td>
<td>5.9 (5.0–8.1)†</td>
<td>NS</td>
</tr>
<tr>
<td>Free thyroxine (pmol/l)</td>
<td>15.45 (14.2–16.7)</td>
<td>15.32 (12.9–16.7)</td>
<td>NS</td>
<td>14.67 (13.4–15.5)†</td>
<td>16.47 (14.2–15.45)*</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Alcohol (g/day)</td>
<td>1.0 (0.38–4.7)</td>
<td>1.58 (0.48–4.4)</td>
<td>&lt; 0.01</td>
<td>0.38 (0.38–1.9)*</td>
<td>0.96 (0.38–4.7)</td>
<td>NS</td>
</tr>
</tbody>
</table>

Discussion

SCH is closely associated with FL, independent of known metabolic risk factors (7, 9). However, there is no clear explanation for this association. It has been suggested that obesity-related SCH (29, 30), and the altered lipid peroxidation (31), which is one of the leading causes of liver cell damage (32), might play a role in the association between hypothyroidism and hepatic steatosis. On the other hand, an increase in fatty acids in hepatic steatosis might inhibit T₄ to tri-iodothyronine conversion, which in turn perpetuates fat accumulation in the liver (15). The possibility that insulin resistance and MS result in hepatic lipid accumulation and FL in the SCH subjects cannot be excluded by the results of this study. Thus, at present, the question of causality remains unanswered. Regardless of the direction of causality, the novel findings of this study are that, compared with euthyroid and SCH individuals without FL, subjects with SCH FL(+) had a significantly higher prevalence of abdominal obesity, VAT excess,
Table 2  Association of thyroid function with metabolic syndrome, insulin resistance, and coronary artery calcification according to the presence of FL. Values are expressed as odds ratios (95% CI), obtained by multivariate logistic regression analyses.

<table>
<thead>
<tr>
<th></th>
<th>Metabolic syndrome</th>
<th>HOMA-IR elevated</th>
<th>Coronary artery calcification score &gt; 0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model 1a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EU FL(−)</td>
<td>Reference</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>EU FL(+)</td>
<td>1.63 (1.11–2.39)</td>
<td>4.34 (2.79–6.80)</td>
<td>0.87 (0.54–1.41)</td>
</tr>
<tr>
<td>SCH FL(−)</td>
<td>0.92 (0.55–1.54)</td>
<td>1.01 (0.62–1.65)</td>
<td>0.78 (0.42–1.48)</td>
</tr>
<tr>
<td>SCH FL(+)</td>
<td>3.28 (1.56–6.94)</td>
<td>7.23 (2.40–21.83)</td>
<td>2.75 (1.18–6.42)</td>
</tr>
<tr>
<td>Model 2b</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EU FL(−)</td>
<td>Reference</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>EU FL(+)</td>
<td>1.63 (1.11–2.39)</td>
<td>3.83 (2.43–6.05)</td>
<td>1.02 (0.61–1.69)</td>
</tr>
<tr>
<td>SCH FL(−)</td>
<td>0.89 (0.53–1.53)</td>
<td>0.93 (0.55–1.57)</td>
<td>0.73 (0.37–1.43)</td>
</tr>
<tr>
<td>SCH FL(+)</td>
<td>2.73 (1.26–5.92)</td>
<td>4.91 (1.63–14.75)</td>
<td>3.05 (1.20–7.76)</td>
</tr>
</tbody>
</table>

*Model 1: adjusted for age, gender, and BMI.
*Model 2: adjusted for age, gender, BMI, visceral adipose tissue, high-sensitivity C-reactive protein, free thyroxine, and LDL-C. Additional adjustment for metabolic syndrome components – triglycerides, HDL-C, hypertension, and fasting glucose – was done in the coronary artery calcification score > 0. EU, euthyroidism; FL, fatty liver; SCH, subclinical hypothyroidism.

reported associations between SCH and CHD. An interesting recent study by Sert et al. (35) has demonstrated that obese adolescents with FL and SHC had a proatherogenic metabolic risk factor profile and a higher carotid intima-media thickness and left ventricular mass. Our results obtained for adults confirm the observations of that study. Inconsistencies among studies may be explained by the differences in the study design, sample size, characteristics of the populations studied, and criteria used to define thyroid dysfunction. However, our finding that only SCH patients with FL showed significant positive correlations with metabolic abnormalities and subclinical atherosclerosis, even after adjustment for confounding factors including abdominal VAT, suggests that increased hepatic fat may contribute directly to the association of SCH with these conditions, and that the discrepant results among previous studies investigating relationships between SCH and metabolic factors could reflect varying severity and prevalence of FL both between subjects within studies and between studies.

The role of FL as a factor influencing the association of SCH with cardiometabolic risk factors and the presence of a CAC score > 0 is supported by studies demonstrating that an increased intrahepatic fat content is associated with these conditions. In an investigation conducted in 2589 individuals, Speliotes et al. (36) found that after adjustment for VAT and other fat depots, FL measured by computed tomography was significantly associated with diabetes, hypertension, impaired fasting glucose, MS, HDL-C, triglycerides, and adiponectin levels. In another study using euglycemic hyperinsulinemic clamps, Fabbrini et al. (37) found a significantly greater insulin resistance in liver, adipose, and muscle tissues from obese subjects with NAFLD compared with that observed in obese subjects without NAFLD, even though the two groups had been matched for VAT volume. With regard to the association between FL and CAC score > 0, two recent studies involving large numbers of subjects showed that the association remained significant after controlling for traditional cardiovascular risk factors, including VAT (38) or pre-existing cardiovascular disease (39). Taken together, our results and those of other studies (36, 37, 38, 39) strongly suggested that hepatic fat is intimately involved in the pathogenesis of metabolic abnormalities and subclinical atherosclerosis present in subjects with FL. The adverse cardiovascular risk profile found in subjects with SCH plus FL may serve as a marker of long-term cardiovascular risk and may explain some of the previously observed associations between SCH and cardiovascular disease (10, 33).
Limitations

This study has some potential limitations. First, because of the cross-sectional nature of this study and the relatively small number of subjects with SCH and FL, caution should be exercised in interpreting our findings, which should be considered as a hypothesis generated and confirmed by studies with a larger number of subjects. Secondly, the diagnosis of FL was performed by CT scans with the exclusion of viral hepatitis B and C. HIV/AIDS, syphilis, and Chagas disease were also excluded. However, other causes of potential abnormality in liver density measured by CT such as viral hepatitis A, D, E, and G, autoimmune hepatitis, metabolic liver disease, anti-trypsin deficiency, Wilson’s disease, hemocromatosis, and celiac disease were not excluded. Thirdly, the diagnosis of FL by CT was not confirmed by liver biopsies. However, a significant correlation has been demonstrated between the liver attenuation images on CT and the histological grade of steatosis (40). Fourthly, we did not measure insulin resistance by more sophisticated approaches such as the euglycemic clamp; however, the HOMA index has proven to be a reliable measure of insulin sensitivity in non-diabetics (41).

Conclusions

In summary, our data strongly suggest that in subjects with SCH, the increased liver fat content, and not low thyroid function, is more predictive of metabolic abnormalities and the presence of CAC, a surrogate marker of atherosclerosis. Further clinical and experimental studies may be warranted to validate our findings and determine whether correction of FL could contribute to the improvement of the metabolic derangement and reduce cardiovascular risk.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by a grant from Mexico’s Consejo Nacional de Ciencia y Tecnología (project # SALUD-2010-2-150537).

Author contribution statement

C Posadas-Romero, E Jorge-Galarza, R Posadas-Sánchez, and E Kimura-Hayama participated in conception, design, analysis, interpretation of data, and the final approval of the manuscript submitted. J Acuña-Valerio, J G Juárez-Rojas, A Medina-Urrutia, and G C Cardoso-Saldana drafted the manuscript and revised it critically for important content.

Acknowledgements

The authors thank all staff and subjects who participated in this study.

References

15. Ittermann T, Haring R, Wallaschofski H, Baumestet SE, Nauck M, Dörr M, Lorch MM, Meyer zu Schwabedissen HE, Rosskopf D & Volke H. Inverse association between serum free thyroxine levels...


